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Both activation of platelets and elevation of plasminogen activator 
inhibitor type 1 (PAI-l) activity in plasma have been associated 
with acute myocardial infarction. Growth factors from platelet 
alpha-granules have been shown to increase PAI-l synthesis in 
liver and endothelial cells in culture. The present study was 
designed to determine whether activation of platelets in vivo 
increases PAI-l activity in plasma, thereby potentially attenuating 
thrombolysis. 
Carotid arteries in rabbits were stimulated with transluminal 
anodal current to initiate thrombosis manifested initially by cyclic 
flow variations known to reflect platelet activation. Flow was 
monitored with Doppler flow probes. Plasma PAI-l activity (mean 
± SEM) assayed spectrophotometrically increased from 6.8 ± 0.8 
arbitrary units (AU)/ml to a peak of 19.1 ± 2.9 AU/ml (n = 15) 
4.8 ± 0.6 h after the onset of cyclic flow variations. The magnitude 
of peak PAI-l values correlated closely with the frequency and 
duration of antecedent cyclic flow variations. 
Despite its unequivocal utility, thrombolysis for the treat-
ment of acute myocardial infarction is limited to some extent 
by failure of recanalization of the occluded infarct-related 
artery (in as many as 20% of patients) and by early reocclu-
sion (in ~ 12%) after initially successful recanalization (1 ,2). 
Furthermore, recanalization may be delayed for ~~ h, 
obviating optimal salvage of jeopardized myocardium (3). 
Mechanisms responsible for delayed recanalization and 
early reocclusion have not been completely elucidated, but 
activation of platelets appears to contribute (4,5). Platelets 
are major constituents of arterial thrombi, and intensified 
recruitment of platelets may accompany coronary thrombol-
ysis because of pro thrombotic effects of plasmin or elabora-
tion of procoagulant molecules from clots undergoing lysis, 
or both (6,7). 
Platelets contain substantial quantities of plasminogen 
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Complete thrombotic occlusion did not elevate PAI-l beyond 
that seen with severe, repetitive partial occlusions (1~.7 ± 4.6 vs. 
19.6 ± 3.8 AU/ml). However, when recanalization of completely 
occluded vessels was induced with tissue-type plasminogen activa-
tor (t-PA), plasma PAI-l increased more markedly (from 5.6 ± 
0.7 to 112.8 ± 22.3 AU/ml, n = 11), exceeding the increase after 
corresponding intervals in animals in which t-PA failed to induce 
recanalization (from 5.2 ± 1.1 to 28.3 ± 6.1 AU/ml, n = 6). 
Thus, activation of platelets accompanying thrombosis or 
thrombolysis, or both, markedly increases PAI-l activity in 
plasma. Our results are consistent with the view that release of 
products from activated platelets in the setting of thrombolysis can 
increase synthesis of PAI-l, thereby attenuating thrombolysis. 
They suggest that optimal pharmacologic thrombolysis will re-
quire concomitant inhibition of activation of platelets or obviation 
of augmented synthesis of PAI-l, or both. 
(JAm Coli Cardiol1991;18:1547-54) 
activator inhibitor type 1 (P AI -I), the physiologic inhibitor 
of tissue-type plasminogen activator (t-PA) and urokinase. 
We have shown that products such as growth factors pres-
ent in platelet alpha-granules can induce synthesis of PAI-l 
in vitro and in vivo (8-10) and that plasma PAI-l activity 
is increased after acute myocardial infarction in patients 
(II). Accordingly, it appeared likely to us that activation 
of platelets accompanying coronary thrombosis or throm-
bolysis, or both, may increase plasma PAI-l activity 
in vivo. 
The present study was performed to determine whether 
plasma P AI -1 activity is increased by activation of plate-
lets induced by endothelial injury and thrombosis reflected 
by cyclic flow variations or complete occlusion. We also 
attempted to assess whether this increase is accentuated 
by thrombolysis induced with t-PA. To accomplish these 
goals, endothelial injury was induced electrically in carotid 
arteries of rabbits. Arteriovenous shunts were implanted to 
preclude embolization to the brain when the thrombi were 
lysed with recombinant tissue-type plasminogen activator 
(rt-PA). This approach was employed so that occlusion and 
lysis could be induced without concomitant end organ ne-
crosis that might otherwise influence synthesis of PAI-l in 
vivo. 
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Methods 
Experimental Procedures 
Effects on plasminogen activator inhibitor type-1 (P AI -1) of 
vascular injury manifested by cyclic flow variations with or 
without subsequent complete thrombotic occlusion. The pro-
tocol conformed to the "Position of the American Heart 
Association on Research Animal Use" (November 11, 1984) 
and was approved by the Animal Studies Committee at 
Washington University. Endothelial injury was induced by 
transmural carotid artery electrical stimulation in New 
Zealand White rabbits (weighing 3 to 4.3 kg) anesthetized 
with thiopental sodium (25 mg/kg body weight) given 
through a marginal ear vein. The right carotid artery was 
exposed, and a 2-mm Doppler flow probe was positioned 
proximally around the vessel. An electrode comprising a 
2-mm wide band of braided stainless steel insulated with 
silicon adhesive and Silastic tubing on the outer surface was 
secured distally around the artery. Lead wires of the elec-
trode and flow probe were brought to the surface through a 
small dorsal incision in the neck. Incisions were closed and 
the rabbits were allowed to recover for 5 to 7 days, at which 
time plasma PAI-l activity had returned to baseline values. 
On the days of experiments, the rabbits were placed in 
holders with minimal restraint and sedated with morphine 
(0.5-mg/kg total dose). This regimen had no discernible effect 
on platelet aggregation ex vivo. The implanted electrode was 
connected to a 50-kil potentiometer, an ammeter and the 
anode of a 9-V battery, with the circuit completed with a 
ground to subcutaneous tissue. The Doppler probe permitted 
continuous recording of the pulsatile blood flow velocity. 
Thrombosis was induced by passing a 300 to 400-,uA current 
through the electrode until cyclic flow variations, character-
ized by intermittent partial thrombotic occlusions followed 
by abrupt spontaneous recanalizations indicative of platelet 
accumulation and dislodgement, were evident from the 
Doppler flow tracing as described by Folts eta!. (12). Serial 
blood samples (2 ml total) were obtained from a central ear 
artery with a two-syringe technique and plastic syringes, 
transferred immediately into tubes maintained at oo to 4°C 
containing 12.9 mM of sodium citrate (10) and centrifuged at 
2,000 g for 20 min. Plasma was frozen immediately in liquid 
nitrogen, and samples were stored at - 70°C for subsequent 
assay. Sample volumes were replaced with equal volumes of 
0.9% sodium chloride to avoid marked changes in plasma 
volume. 
Effects of thrombolysis on concentrations of PAI-l in 
plasma. After the initial experiments had been completed, 
additional and more prolonged studies were required to 
define the effects of thrombolysis on PAI-l in plasma hours 
after its induction. Anesthesia was implemented with 
20 mg/kg of ketamine intramuscularly (Ketalar, 100 mg/ml) 
and 8 mg/kg of xylazine intramuscularly (Rompun, 100 mg/ml). 
Additional intramuscular injections were used as needed. To 
determine the effect of lysis of thrombi on PAI-l activity, an 
arteriovenous shunt was inserted between the right carotid 
artery and left external jugular vein with a 5-cm length of 
saline-filled silanized polypropylene tubing (inner diameter 
1.57 mm, outer diameter 2.41 mm) (Churchill Medical Sys-
tems). This procedure avoided induction of cerebral infarc-
tion when the carotid thrombi were subsequently lysed. 
After blood flow through the shunt had been established, 
thrombosis in the native carotid artery was induced as 
previously described (13) with a needle electrode inserted 
transmurally into the lumen (a 23-gauge needle with its tip 
crimped on the bare end of a 30-gauge Teflon insulated silver 
wire) (A-M Systems). To minimize leakage of current to 
perivascular tissue, a polyethylene sleeve was positioned 
over the junction of the needle and the wire. 
The needle electrode was inserted obliquely approxi-
mately 2 mm into the arterial lumen and stabilized with 
sutures through tissue on either side of the vessel. Current 
(200 ,uA) was applied through the electrode until occlusive 
thrombosis was complete as verified by zero flow velocity. 
Thirty minutes later, rt-PA was infused intravenously at a 
dose of 5 mg/kg (8 x 105 IU/mg; Genentech) over 60 min, 
with l 0% of the total dose infused as a bolus during the first 
2 min. Infusions were controlled with the use of a pump 
(syringe infusion pump 22, Harvard Apparatus). Because 
rabbits are more resistant to rt-PA than are dogs, a large 
dose was used. Peak t-PA antigen levels in plasma averaged 
25 ,ug/ml, approximately fivefold greater than values in 
previous studies we performed in dogs (14). 
Recanalization was reflected by a return of average flow 
velocity to ::::50% of baseline values. All rabbits were given 
heparin (200 U/kg) and a soluble preparation of aspirin 
(lysine-acetylsalicylic acid, 30 mg/kg) intravenously over 
2 min, beginning 3 min before the infusion of rt-PA. Flow 
velocity was monitored continuously, and blood samples 
were collected serially after completion of the infusion of 
rt-PA. 
Biochemical Procedures 
Tissue plasminogen activator (t-PA) antigen was deter-
mined by enzyme-linked immunosorbent assay (American 
Diagnostica). Alpha2-antiplasmin was assayed spectrophoto-
metrically as previously described (15). Blood leukocyte and 
platelet counts were determined conventionally with a 
hemocytometer. 
Plasminogen activator inhibitor (PAI-l) activity. This was 
assayed spectrophotometrically in citrated plasma with a 
modification of the assay developed by Chmielewska and 
Wiman (16) as described previously. One arbitrary unit (AU) 
of plasma PAI-l activity was defined as the amount inhibit-
ing l international unit (IU) of t-PA in a 10-min interval. 
Standard curves were obtained with serial dilutions of 
pooled rabbit plasma. Results were expressed as arbitrary 
units per milliliter (AU/ml). The interassay coefficient of 
variation was <5%. 
For assay of PAI-l protein, plasma samples were sub-
jected to sodium dodecyl sulfate-polyacrylamide gel electro-
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phoresis (SDS-PAGE) after first being incubated at 25°C 
for 15 min in the presence of rt-PA (final concentration 
500 IU/ml). Immunoprecipitation of t-PA/PAI-1 complexes 
in plasma samples was performed with affinity purified 
antibodies to t-P A that had been covalently coupled to 
activated microspheres as previously described (17). The 
SDS-PAGE of immunoprecipitates on minislab gels (Mini 
Protean II, Bio-Rad) was performed with Laemmli buffers, 
resolving gels of 10% acrylamide and stacking gels of 4% 
acrylamide (18). 
Western blotting. This was performed with polyvinyli-
dene difluoride membranes (Millipore) after electrostatic 
transfer (100 V, 45 min, 4°C, Transblot apparatus, Bio-Rad) 
of nonreduced samples fractionated by SDS-PAGE as de-
scribed previously (17). Membranes were incubated with 
10 JLg/ml of a goat antibody to t-PA (American Diagnostica), 
and immune complexes were detected with iodine-125-
donkey antigoat immunoglobulin (lg) (Sigma) by autoradiog-
raphy. Bands of interest on autoradiograms were quantified 
by laser densitometry (Ultrascan XL, Pharmacia LKB Bio-
technology). 
Fibrin autography. Some of the rabbit plasma samples 
incubated initially with rt-PA were diluted 1:20. Then 10-JLl 
aliquots were subjected to SDS-PAGE and analyzed by 
fibrin autography as previously described (19). Reverse 
fibrin autography was performed as described by Loskutoff 
et al. (20). All biochemical assays were performed within 1 
week of acquisition of samples. 
Histology of thrombi and vessels. At the completion of 
experiments, cardiac arrest was induced with an overdose of 
thiopental sodium and potassium chloride. To determine the 
composition of thrombi that had been induced by electrical 
injury of the carotid wall, arteries with complete occlusion 
were ligated proximal and distal to the thrombus. The 
isolated arterial segment was excised and opened longitudi-
nally. Thrombotic material and the vessel were inspected, 
sectioned serially and fixed in 10% formalin for light micros-
copy. 
Statistical analysis. Data are presented as mean values ± 
SEM. Comparisons between groups were made with two-
tailed Student's t tests for paired or unpaired observations as 
appropriate. Wilcoxon's nonparametric test was used for 
analysis of data that had unequal standard deviations. Rela-
tions between PAI-l activity and cyclic flow variations were 
assessed by linear regression analysis. Pearson correlation 
coefficients were calculated; a p value ::s0.05 was considered 
to indicate a significant difference. 
Results 
Effects of thrombosis-induced cyclic flow variations with or 
without complete occlusion on plasma plasminogen activator 
inhibitor type-1 (PAI-l) activity. Administration of aspirin, 
recombinant tissue-type plasminogen activator (rt-PA) or 
heparin in rabbits in which thrombosis was not induced did 
not affect plasma PAI-l activity (n = 3). Alpha2-antiplasmin 
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Figure 1. Effects of vascular injury manifested by cyclic flow 
variations and thrombosis on plasma plasminogen activator inhibitor 
type 1 (PAI-l) activity. Top, Plasma PAI-l activity at baseline (n == 
15), peak values after induction of vascular injury (n = 15) and 
values 24 h after induction of vascular injury (n = 9). Bottom, Effects 
of thrombosis (occlusion) on peak plasma PAI-l activity. Peak 
plasma PAI-l activity in rabbits with cyclic flow variations followed 
by complete thrombotic occlusion (n = 8) ( +) is compared with 
activity in rabbits in which complete occlusion did not occur (n = 7) 
(- ). 
in plasma after induction of vascular injury did not change 
appreciably (98 ± 2% of baseline value after 3 h, [n == 12]; 
99 ± 1% after 5 h [n == 4]; 110 ± 3% after 24 h [n = 9]). As 
expected, introduction of cathodal as opposed to anodal 
current to induce thrombosis did not elicit an increase in 
PAl -1 activity (n = 2) nor did carotid occlusion induced by 
ligation (n = 2). Electrical injury to the carotid artery giving 
rise to thrombosis did, however, augment PAI-l activity 
after a substantial delay. Histologic examination demon-
strated that the induced thrombi were rich in both platelets 
and fibrin. 
In initial experiments in which electrical vascular injury 
was implemented, cyclic flow variations were induced in 13 
(87%) of 15 rabbits. Among all animals, PAI-l activity in 
plasma increased significantly from an average baseline 
value of6.8 ± 0.8 AU/ml to a peak value of 19.1 ± 2.9 AU/ml 
(Fig. 1, top). In the two rabbits in which cyclic flow 
variations were not detectable, PAI-l activity increased less 
markedly to peak values of only 8.5 and 8.3 AU/ml. Peak 
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PAI-l activity occurred 4.8 ± 0.6 h after the onset of 
vascular injury. Complete occlusion occurred ultimately in 
eight rabbits (62%) at an average of 124 ± 17 min (range 66 
to 199) after the onset of vascular injury. Plasma PAI-l 
activity returned toward baseline values (12.2 ± 1 AU/ml) in 
24 h, but remained significantly elevated. 
To determine whether the magnitude of the increase in 
PAI-l activity was related to the presence or absence of 
complete thrombotic occlusion, peak PAI-l activity was 
compared in rabbits with or without complete occlusion. 
Peak PAl -1 values were similar in the two groups at baseline 
study (6.4 ± 0.7 and 7.2 ± 1.4 AU/ml) and 24 h after the 
onsetofinjury(12.1 ± 1 and 12.5 ± 3.1 AU/ml). Peak PAI-l 
activity occurred 5 ± 0.9 h after the onset of injury in 
animals with complete occlusion and 4.6 ± 0. 7 h in those 
without complete occlusion. The presence of complete oc-
clusion did not increase peak PAI-l activity (18.7 ± 
4.6 AU/ml) beyond that seen without complete occlusion 
(19.6 ± 3.8 AU/ml) (Fig. 1, bottom). However, peak PAI-l 
activity was significantly correlated with both the frequency 
of cyclic flow variations and the duration of the interval 
during which cyclic flow variations persisted in rabbits with 
and without ultimately complete occlusion (Fig. 2). 
The capacity of PAI-l to bind t-PA in rabbit plasma 
samples obtained before and after induction of vascular 
injury eliciting cyclic flow variations and thrombosis was 
measured by Western blotting. When samples were supple-
mented with an excess ofrt-PA, the formation ofPAI-1/t-PA 
complexes with an apparent molecular weight of I 00 kDa 
was observed (Fig. 3). Densitometric analysis of the PAI-l/ 
t-PA bands on autoradiograms showed that total plasma 
PAI-l antigen had increased by 3.3 ± 0.8-fold (n = 5) after 
induction of vascular injury, consistent with the observed 
parallel increase in PAl -1 functional activity in the same 
samples. 
Effects of Thrombolysis on Plasma PAI-l 
In 6 of 17 rabbits in which persistent complete thrombotic 
occlusion was induced an average of 79 ± 15.2 min after 
initiation of electrical stimulation, infusion of rt-PA did not 
induce recanalization. In 11 animals, it did in an average of 
35.7 ± 4. 9 min. There was no difference in the initial time to 
occlusion or peak t-PA antigen levels in the two groups 
(Table 1). Recanalization was compromised by partial reoc-
clusion reflected by cyclic flow variations in 4 (36%) of the 11 
rabbits in which it had been induced by rt-PA and by 
complete thrombotic reocclusion in 3 (27%) of the 11. 
Compromise of recanalization did not occur while rt-PA was 
being infused. It occurred only after the 1-h infusion had 
been completed at an average of 109 ± 19.1 min after initial 
recanalization. 
Persistent occlusion versus recanalization. Plasma PAl -1 
activity increased significantly from 5.2 ± 1.1 AU/ml at 
baseline to 28.3 ± 6.1 AU/ml (p < 0.05) after thrombosis had 
been induced in rabbits in which occlusion persisted despite 
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Figure 2. Peak plasma plasminogen activator inhibitor type I 
(PAI-l) activity as a function of the frequency of cyclic flow 
variations (CFV) (top) and the interval during which cyclic flow 
variations persisted (bottom). Peak plasma PAI-l activity was di-
rectly proportional to both the frequency and the duration of the 
interval in which episodes of cyclic flow variations occurred. 
administration of rt-PA. These values resembled those after 
occlusion in rabbits that were not given rt-P A (Fig. 1, 
bottom). However, when infusion of rt-PA did induce reca-
nalization, a further marked increase in peak plasma PAI-l 
activity occurred; PAI-l increased from an average baseline 
value of 5.6 ± 0.7 AU/ml to a peak value of 112.8 ± 
22.3 AU/ml (p < 0.001). The increase was significantly 
greater than that in rabbits without recanalization despite the 
similarity of baseline PAI-l values (Fig. 4). 
In rabbits with recanalization, PAI-l activity tended to be 
higher than that in rabbits without recanalization beginning 
2 h after the onset of infusion of rt-PA. The increases were 
consistent and significant 4 and 5 h after the onset of infusion 
(Fig. 5). 
Fibrinolytic activity. Fibrin autography confirmed the 
presence of increased PAI-l activity. Analysis of plasma 
samples obtained after induction of thrombolysis with rt-PA 
demonstrated fibrinolytic activity only in the region corre-
sponding to the locus of the PAI-1/t-PA complex, consistent 
with persistence of complexes in the circulation, as we 
reported previously (11). No fibrinolytic activity was evident 
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Figure 3. The binding capacity of plasminogen activator inhibitor 
type I (PAI-l) for tissue-type plasminogen activator (t-PA) in rabbit 
plasma samples obtained before and after the induction of cyclic 
flow variations (CFV). A representative autoradiogram of immuno-
blots of immunoprecipitates from nonreduced plasma samples that 
had been supplemented with rt-PA is shown. Arrows indicate bands 
of particular interest. The 100-kDa PAI-1/t-PA complex, which is 
faint in plasma samples before cyclic flow variations, is more intense 
in samples obtained after cyclic flow variations had been induced. 
Bands of 55 kDa and 45 kDa indicate free t-PA and a proteolytic 
product of predominantly two-chain t-PA previously observed (I 7). 
Minor bands at 170 and II 0 kDa represent complexes of t-P A with 
Cl-esterase inhibitor and alpha2-antiplasmin, respectively (17). 
in regions corresponding to the locus of single-chain or 
two-chain free t-PA. When samples were incubated with 
exogenous rt-PA, the formation of PAI-l/t-PA complexes 
was evident, consistent with the presence of high concentra-
tions of PAI-l activity before the addition of rt-PA to the 
samples (Fig. 6, top). The 55-kDa t-PA band was attenuated 
in plasma with high PAl -1 activity in which the 1 00-kDa band 
appeared, indicating formation of PAl -1/t-P A complexes that 
are less fibrinolytically active than free t-PA. 
To further document the persistence of functional activity 
associated with increased PAI-l in vivo, rt-PA (1 mg/kg) was 
Table 1. Effects of Recombinant Tissue-Type Plasminogen 
Activator (rt-PA) in 17 Rabbits With Carotid Artery Thrombus 
Time to Initial Peak t-PA antigen 
Recanalization No. Occlusion (min) (J.tg/ml plasma) 
Not induced 6 79.4 ± 19.1 24.9 ± 3.6 
Induced II 78.8 ± 20.6 25.1 ± 3 
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Figure 4. Peak plasminogen activator inhibitor type I (PAI-l) activ-
ity in samples from rabbits with or without recanalization after 
infusion of recombinant tissue-type plasminogen activator. Open 
circles indicate mean values ± SEM. Compared with values in 
rabbits without recanalization (- ), PAI-l increased markedly in 
rabbits with recanalization ( + ). 
administered by bolus injection intravenously in two rabbits 
in which rt-PA had induced recanalization. As was the case 
in our previous studies of endotoxin-pretreated rabbits given 
rt-PA (17), attenuation of free t-PA bands on fibrin auto-
graphs was associated with the appearance of the 100-kDa 
band representing PAI-1/t-PA complexes. In addition, a 
46-kDa inhibitor of fibrinolysis consistent with free PAI-l 
was detected by reverse fibrin autography in plasma samples 
obtained after rt-P A had induced recanalization (Fig. 6, 
bottom). 
Hematologic and microscopic changes. There were no 
significant changes in platelet or leukocyte counts during 
experiments. Alpha2-antiplasmin values in plasma from rab-
Figure 5. Effects of thrombolysis on plasma plasminogen activator 
inhibitor type I (PAI-l) activity. Plasma PAI-l activity as a function 
of time after the onset of infusion of recombinant tissue-type 
plasminogen activator (t-PA) is shown for rabbits with (n = ll) and 
without (n = 6) recanalization. After induction ofthrombosis, PAI-l 
activity increased in both groups. An additional marked increase 
occurred after thrombolysis was induced. 
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Figure 6. Top, Representative fibrin autographs of sequentially obtained 
plasma samples. Arrows indicate bands of interest. Lane 1 = baseline 
sample; lane 2 = sample obtained 4 h after recanalization induced with 
tissue-type plasminogen activator (t-PA). Activity associated with free 
t-PA (55 kDa) decreased and that associated with the t-PA/plasminogen 
activator inhibitor type I (PAI-l) complex (100 kDa) increased markedly 
4 h after recanalization. The faint lytic zone at 170 kDa is attributable to a 
complex oft-PA with Cl-esterase inhibitor (11). Bottom, Representative 
reverse fibrin autographs showing inhibitors of fibrinolysis detected after 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Light areas show areas without lysis of fibrin. Lane I = baseline plasma 
sample; lane 2 = sample obtained 5 h after recanalization induced with 
recombinant tissue-type plasminogen activator. Inhibitory activity was 
not seen in the baseline sample (lane 1), but was present in the sample 
obtained 5 h after recanalization (lane 2) associated with a 46-kDa protein 
band, consistent with the molecular weight of PAI-l (arrow). 
bits not given rt-PA did not change appreciably (103 ± 4% of 
baseline value at 3 h after the initiation of current [ n = 6]; 100 
± 5% at 6 h [n = 6]). Histologic studies demonstrated that 
thrombi induced by electrical injury with the needle elec-
trode in rabbits with carotid artery-jugular vein shunts were 
platelet rich. 
Discussion 
Role of platelets in increased plasma plasminogen activator 
inhibitor type 1 (PAI-l) activity. We previously showed that 
purified growth factors present in platelet alpha-granules and 
autologous platelet lysates can induce synthesis of PAI-l in 
Hep G2 cells (8,9) and human umbilical vein endothelial cells 
in vitro (21); that their effects are specific (being blocked by 
antibodies to the same growth factors) (8,21); that platelet 
lysates in low concentrations corresponding to <4% of the 
concentration of platelets in blood induce marked increases 
in circulating plasma PAI-l activity in vivo in rabbits; and 
that the increases in PAI-l activity in vivo are accompanied 
by increased steady state PAl -1 messenger ribonucleic acid 
(mRNA) levels in liver, heart and aorta (10). 
The present study was designed to determine whether the 
physiologic activation of platelets in vivo, known to be 
associated with lesions giving rise to cyclic flow variations 
and with thrombolysis in vivo (6,7,22), induces comparable 
increases in plasma P AI -1 activity. Such increases would be 
consistent with the hypothesis that the release of platelet 
products associated with activation of platelets in patients 
with coronary thrombosis or coronary thrombolysis, or 
both, contributes to the increased plasma PAI-l activity 
evident in patients with acute myocardial infarction (11) and 
attenuates pharmacologic and endogenous fibrinolysis, re-
ducing its overall clinical efficacy. 
Role of arterial thrombosis. Our results indicate that 
induction of arterial thrombosis giving rise to cyclic flow 
variations leads also to increased plasma PAI-l several 
hours later and induction of lysis of complete thrombotic 
occlusions elicits even more marked increases in PAl -1. 
Cardiac or cerebral ischemia and hematologic changes that 
might accompany induction of anesthesia and surgery could 
induce platelet activation or increase PAI-l through mecha-
nisms that may be entirely different from those attributable 
to activation of platelets associated with thrombosis (22,23). 
Accordingly, we initially used a conscious animal prepara-
tion in which thrombosis could be induced after perturba-
tions attributable to the surgical insult had abated. For 
studies of effects of thrombolysis, we modified the prepara-
tion and the mode of induction of thrombosis. Magnitudes of 
elevation of P AI -I after thrombosis and the composition of 
thrombi were comparable in the two preparations. Further-
more, the induced thrombi were comparable grossly and 
microscopically to human coronary artery thrombi. The 
resistance of some of the induced thrombi to lysis by even 
large doses ofrt-PA was probably attributable to the platelet-
rich nature of the thrombus formed by electrode-induced 
vascular injury (13). 
The marked but delayed increases in plasma PAI-l activ-
ity seen after thrombosis manifested by cyclic flow varia-
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tions or complete occlusion are consistent with the time 
course of increased P AI -1 in response to platelet lysates we 
have observed previously and accordingly with release of 
growth factors associated with activation of platelets. Plas-
minogen activator inhibitor type-1 was not increased further 
by complete occlusion compared with cyclic flow variations 
alone, suggesting that the process of thrombosis and platelet 
activation rather than interruption of blood flow was respon-
sible. The prolonged interval between induction of thrombo-
sis and increases in PAI-l and the known short half-life of 
PAI-l in the circulation (24) suggest that the increased PAI-l 
did not come from platelets themselves, but rather reflected 
delayed increased endogenous synthesis. 
Role of thrombolytic therapy. Thrombolysis induced by 
rt-PA led to the most marked increase in plasma PAI-l 
activity. Activation of platelets is known to occur when 
thrombi are lysed in experimental animals and in patients. 
Factors that induce activation of platelets at sites of recana-
lization have not been fully elucidated. Platelets may be 
activated by plasmin or by plasmin-dependent induction of 
thrombin activity (25). Such activation may explain the 
markedly increased concentrations of P AI -1 in rabbits in 
which recanalization occurred. Activation may also occur as 
a result of exposure of platelets to collagen in the vessel wall 
at sites of vascular injury and endothelial denudation or to 
residual thrombi that are richly endowed with procoagulant 
proteins including thrombin (26). The peak plasma PAI-l 
elevation occurred 4 to 5 h after recanalization. Thus, it 
appeared to reflect increased synthesis analogous to that 
seen in our previous studies of effects of platelet lysates (10). 
Role of aspirin and heparin. Because of the dependence 
of ongoing thrombosis on platelets in the experimental 
system used, aspirin was given to all rabbits to accelerate 
recanalization and retard reocclusion as previously de-
scribed (22). Accordingly, the independent effects of aspirin 
on activation of platelets and stimulation of P AI -1 were not 
evaluated. However, our results indicate that even with 
marked inhibition of thromboxane A2 and thrombin with 
aspirin and heparin, the platelet activation-dependent in-
crease in PAI-l was not prevented, thus suggesting that 
other mechanisms of platelet activation persisted (for exam-
ple, platelet activating factor-dependent pathways, activa-
tion by collagen in the injured vessel wall, epinephrine-
induced activation, activation secondary to high shear forces 
or activation by thrombin resistant to interaction with the 
heparin-antithrombin III complex, such as clot-associated or 
fibrinogen degradation product-associated thrombin) (25). 
Mechanisms of platelet effects. Mechanisms by which 
platelet activation can increase PAI-l have not been fully 
elucidated. Transforming growth factor beta appears to be 
one factor mediating the response (21). Other platelet-
derived constituents may be involved as well. Other cells 
and their cytokines, such as neutrophils and monocytes that 
are activated by endothelial injury early in association with 
thrombosis, may also contribute (27). 
Clinical implications. Activation of platelets is prominent 
in patients with an acute coronary syndrome (28-31) or 
cerebrovascular accident (32). Activation also occurs when 
thrombolysis is induced pharmacologically (6,7). In experi-
mental animals, activation of platelets reduces the efficacy of 
thrombolytic agents (22,33). Activated platelets potentiate 
coagulation markedly and directly (26). In addition, they 
release growth factors that may augment vascular smooth 
muscle cell proliferation contributing to restenosis after 
coronary angioplasty (34) and increased synthesis of PAI-l 
(8-10). 
Increased plasma PAI-l appears to be an independent 
risk factor for ischemic heart disease (35). Because platelet 
activation can increase plasma P AI -1, pharmacologic inhibi-
tion of platelet activation, when implemented at the time of 
an acute insult, may potentiate thrombolysis (28,36-38) and, 
when implemented over prolonged intervals, may retard the 
evolution of vascular disease reflecting impaired fibrinolysis 
underlying an acute coronary syndrome. From a clinical 
perspective, our results support the view that attenuation of 
activation of platelets otherwise accompanying the use of 
thrombolytic agents in patients with acute myocardial in-
farction will diminish subsequent increases in the synthesis 
of PAI-l and thereby diminish the likelihood of early reoc-
clusion attributable to attenuation of endogenous fibrino-
lysis. 
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